Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Sep 5;36(37):5519-5523.
doi: 10.1016/j.vaccine.2018.07.064. Epub 2018 Aug 10.

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine

Sajjad Desai  1 , Niraj Rathi  2 , Anand Kawade  3 , Padmasani Venkatramanan  4 , Ritabrata Kundu  5 , Sanjay K Lalwani  6 , A P Dubey  7 , J Venkateswara Rao  8 , D Narayanappa  9 , Radha Ghildiyal  10 , Nithya J Gogtay  11 , P Venugopal  12 , Sonali Palkar  6 , Renuka Munshi  10 , Ashish Bavdekar  3 , Sanjay Juvekar  3 , Nupur Ganguly  5 , Prabal Niyogi  5 , Kheya Ghosh Uttam  5 , Alpana Kondekar  10 , Dipti Kumbhar  10 , Smilu Mohanlal  10 , Mukesh C Agarwal  11 , Parvan Shetty  11 , Kalpana Antony  2 , Bhagwat Gunale  1 , Abhijeet Dharmadhikari  1 , Jagdish Deshpande  13 , Uma Nalavade  13 , Deepa Sharma  13 , Anurag Bansal  14 , Yuxiao Tang  15 , Jorge Flores  15 , Prasad S Kulkarni  16
Affiliations
Clinical Trial

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine

Sajjad Desai et al. Vaccine. .

Abstract

Background: A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL®) was tested for its potential effect on the immunogenicity of concomitantly administered EPI vaccines in infants in a randomized controlled study in India.

Methods: In this Phase III, multicenter, open label, randomized, controlled study, three doses of BRV-PV or two doses of Rotarix® and one dose of placebo were given to healthy infants at 6, 10, and 14 weeks of age. Subjects also received three doses of DTwP-HepB-Hib (diphtheria, tetanus, whole-cell pertussis, hepatitis B, and haemophilus influenzae type b conjugate - pentavalent vaccine) and oral polio vaccine concomitantly at 6, 10, and 14 weeks of age and a single dose of inactivated polio vaccine at 14 weeks of age. Blood samples were collected four weeks after the final vaccination to assess immune responses to all the vaccines administered. For diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 antibodies, non-interference was to be supported if the lower limit of the two-sided 90% confidence interval (CI) for the seroprotection rate difference for the BRV-PV group minus the Rotarix® group was >10.0%. For pertussis antibodies, non-interference was to be supported if the lower limit of the two-sided 90% CI for the ratio of geometric mean concentrations (GMCs) was >0.5.

Results: A total of 1500 infants were randomized to either BRV-PV (1125 infants) or Rotarix® (375 infants), of which 1341 completed the study as per the protocol. More than 97% of subjects achieved seroprotective antibody titres against diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 in both groups. The difference in seroprotection rates between the BRV-PV group and the Rotarix® group for all these antibodies was less than 1%. The ratio of GMCs of anti-pertussis IgG concentrations for the BRV-PV group versus Rotarix® was 1.04 [90% CI: 0.90; 1.19].

Conclusion: BRV-PV does not interfere with the immunogenicity of concomitantly administered routine infants vaccines.

Trial registration: ClinicalTrials.gov NCT02584816.

Keywords: Bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV); DTwP-HepB-Hib vaccine; Immune response; Interference; Oral polio vaccine (OPV).

PubMed Disclaimer

References

    1. Tate J.E., Burton A.H., Boschi-Pinto C., Parashar U.D. World Health Organization-coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62(Suppl 2):S96–S105. - PMC - PubMed
    1. Rotavirus vaccines. WHO position paper – January 2013.Wkly Epidemiol Rec 2013 February 1; 88(5): p. 49–64. - PubMed
    1. Immunization coverage. Fact sheet. Updated July 2017. http://www.who.int/mediacentre/factsheets/fs378/en/ [accessed 13.09.17].
    1. Zade J.K., Kulkarni P.S., Desai S.A., Sabale R.N., Naik S.P., Dhere R.M. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124–A128. - PubMed
    1. Naik S.P., Zade J.K., Sabale R.N., Pisal S.S., Menon R., Bankar S.G. Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®) Vaccine. 2017;35(22):2962–2969. - PubMed

Publication types

MeSH terms

Associated data